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There is a general consensus that physical activity should 
be recommended for individuals with type 1 diabetes mel-
litus (T1DM) [1]. While moderate exercise can be relatively 
easily managed with respect to diabetes, extreme or pro-
longed sport activity still remains a challenge [1]. Extreme 
sports are in general not recommended for individuals with 
T1DM, but more and more patients choose them. In such 
cases, diabetes management should be highly individualized, 
and advanced technologies often can be useful [1].
Here we describe the 1008-km non-stop bicycle race suc-
cessfully completed by a 44-year-old individual with 22-year 
duration of T1DM. The patient is physically very active and 
enjoys extreme challenges. His clinical characteristics have 
been presented before [2]. He previously captured Aconca-
gua mountain [2], participated in Damavand expedition [3], 
and completed a trail running ultramarathon, to list only few 
of his achievements. His last available HbA1c determined 
2 months before competition was 6.8% (50.8 mmol/mol), 
current weight 78 kg, and BMI 23.8 kg/m2. Informed con-
sent about using his personal and medical data was obtained 
before the race.
The patient uses The MiniMed 640G system (Medtronic, 
Inc., Northridge, CA, USA) which includes a feature called 
SmartGuard™ that suspends insulin delivery when the 
glucose value is predicted to reach or fall below a preset 
low glucose limit within 30 min and automatically restarts 
basal insulin on recovery from hypoglycemia [4]. Settings 
for suspend before low are customizable. Since the patient 
was switched to a 640G personal insulin pump, his Smart 
Guard™ feature was set to 3.3–3.9 mmol/L (60–70 mg/dL). 
This target was successfully tested in clinical trials and is 
supposed to be effective for glucose management for major-
ity of individuals with T1DM [5]. However, to the author’s 
knowledge it has been never checked under conditions of 
prolonged and extreme exercise.
The Baltic Sea–Bieszczady Mountains bicycle race took 
part during August 24th–27th, the time limit to complete the 
1008-km race was 70 h. The most important challenge with 
respect to glucose management was choosing the proper 
pump settings to successfully prevent hypoglycemia, keep 
blood glucose concentration in a range optimal for prolonged 
aerobic exercise and allow only minimal intervention from 
patient side.
The first question to be addressed before setting the 
SmartGuard™ feature was what should be the target glucose 
levels for heavy, aerobic, 70-h continuous exercise. Based 
on consensus published recently, a reasonable starting range 
for most patients doing aerobic exercise is 7–10 mmol/L 
(126–180 mg/dL), higher concentrations might be advised 
in some situations where added protection against hypogly-
caemia is needed [1]. The maintenance of a concentration 
of about 6–8 mmol/L (108–144 mg/dL) may be ideal [1]. 
Our previous experience from trail ultramarathon pointed, 
however, that SmartGuard™ feature setting at 6.9 mmol/L 
(70 mg/dL) is too low to keep the glucose level during pro-
longed exercise in target. Exercise induces insulin-independ-
ent glucose uptake into muscle [1]. An extended duration 
of exercise leads to decreased reliance on muscle glycogen 
as fuel and increased reliance on lipid oxidation and glu-
cose derived from plasma [1]. Plasma insulin concentrations 
must be kept low, otherwise the rise in counter-regulatory 
hormones will not be effective enough in the promotion of 
hepatic glucose production [1]. One of the priorities during 
prolonged exercise is avoidance of hypoglycemia since each 
hypoglycemic episode decreases patients’ performance sig-
nificantly and in our case of extremely long exercise could 
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result in race discontinuation [1]. This is why we decided 
to set SmartGuard™ option at 90 mg/dL for the whole race. 
Patient successfully completed the race within 68 h and 
4 min in good shape.
During 3-day race, patient’s mean glucose patterns were 
as follows:
– Day 1: mean: 10 mmol/L (180 mg/dL), SD: 3.9 mmol/L 
(70  mg/dL), time in target 45%, time > target 33%, 
time < target 23% (target 3.9–10.0  mmol/mol (70–
180 mg/dL)), total daily insulin dose: 20, 83 IU (72% 
delivered as basal), total time of basal insulin delivery 
suspension: 6 h 41 min.
– Day 2: mean: 11.3 mmol/L (204 mg/dL), SD: 4.4 mmol/L 
(80  mg/dL), time in target 62%, time > target 38%, 
time < target 0%, total daily insulin dose: 26, 4 IU (65% 
delivered as basal), total basal insulin delivery suspen-
sion: 4 h 20 min.
– Day 3: mean: 11 mmol/L (198 mg/dL), SD: 4.6 mmol/L 
(83  mg/dL), time in target 60%, time > target 40%, 
time < target 0%, total daily insulin dose: 30,68 IU (59% 
delivered as basal), total basal insulin delivery suspen-
sion: 4 h 21 min.
Figure 1 shows the insulin pump download from one of 
the race days (hours 4–28).
Insulin pump settings and patient’s glucose management 
resulted in very effective hypoglycemia prevention. The indi-
vidual did not have to manually stop or reduce basal insulin. 
The mean glucose concentration as the number of hypergly-
cemic excursions should be considered to high. This is prob-
ably the result of underbolusing—the total dose of insulin 
delivered as boluses was only 28.2 IU over the 3-day race. In 
addition, hyperglycemic excursions could have also resulted 
from having few large meals not effectively covered with 
insulin boluses instead of multiple meals and snacks. This 
was the patient’s choice with the goal to save time during 
competition. Although there were many hours of suspension 
during the race, we think threshold for suspension was set 
correctly to successfully prevent hypoglycemia which was 
the main target.
To conclude, completing the 1008-km non-stop bike race 
was a phenomenal achievement for a patient with T1DM. 
Setting “suspend before low” target at 5 mmol/L (90 mg/dL) 
allowed the patient to avoid hypoglycemia very effectively. 
However, the performance could be probably even better 
with a lower mean glucose level, which could have been 
achieved with higher meal boluses and/or multiple smaller 
meals/snack rather than few large meals.
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